哺乳期妇女伯氨喹药代动力学及母乳喂养婴儿暴露研究
本研究纳入20对G6PD正常的哺乳期妇女及其婴儿,母亲服用伯氨喹0.5 mg/kg/天共14天。婴儿经母乳估算摄入剂量为2.98 µg/kg/天(约0.6%的假想婴儿日剂量0.5 mg/kg),婴儿样本中伯氨喹和羧基伯氨喹浓度大多低于检测阈值,无药物相关溶血证据。结论认为母乳中伯氨喹浓度很低,极不可能对母乳喂养婴儿造成不良影响,不应因此不给哺乳母亲使用伯氨喹,但新生儿需更多信息。
要点
- 20对G6PD正常母婴中,婴儿经母乳估算伯氨喹摄入量为2.98 µg/kg/天(约0.6%的假想婴儿日剂量0.5 mg/kg)。
- 仅1份婴儿毛细血管血浆样本可测到伯氨喹2.6 ng/mL,羧基伯氨喹在多数婴儿样本中不可测(最高值25.8 ng/mL)。
- 婴儿无药物相关溶血证据,母亲不良事件轻微,母乳中伯氨喹浓度很低,极不可能对母乳喂养婴儿造成不良影响。
核心结论
- 母乳中伯氨喹浓度很低,因此极不可能对母乳喂养婴儿造成不良影响。
- 不应因此不给母乳喂养婴儿或幼儿的母亲使用伯氨喹。
- 新生儿需要更多信息。
研究设计与样本
- 纳入既往有间日疟原虫感染史的健康G6PD正常哺乳期妇女及其28天至2岁的健康G6PD正常婴儿。
- 母亲服用伯氨喹0.5 mg/kg/天共14天。
- 在第0、3、7和13天采集母亲静脉血浆、毛细血管血浆、母乳样本及婴儿毛细血管血浆样本,测定伯氨喹和羧基伯氨喹浓度。
主要发现
- 在20对母婴中,除1份婴儿毛细血管血浆样本含伯氨喹2.6 ng/mL外,其余婴儿样本伯氨喹浓度均低于检测阈值。
- 羧基伯氨喹在多数婴儿样本中不可测,最高值为25.8 ng/mL。
- 基于实测母乳水平估算的婴儿伯氨喹摄入剂量为2.98 µg/kg/天(即约0.6%的假想婴儿日剂量0.5 mg/kg)。
- 婴儿中无药物相关溶血证据。
- 母亲药物水平与非哺乳患者相当,母亲不良事件轻微。
临床怎么用
- 作者结论认为母乳中伯氨喹浓度很低,极不可能对母乳喂养婴儿造成不良影响,不应因此不给母乳喂养婴儿或幼儿的母亲使用伯氨喹。
- 作者指出新生儿需要更多信息。
局限性
- 新生儿需要更多信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primaquine is the only drug providing radical cure of Plasmodium vivax malaria. It is not recommended for breastfeeding women as it causes hemolysis in glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals, and breast milk excretion and thus infant exposure are not known. METHODS: Healthy G6PD-normal breastfeeding women with previous P. vivax infection and their healthy G6PD-normal infants between 28 days and 2 years old were enrolled. Mothers took primaquine 0.5 mg/kg/day for 14 days. Primaquine and carboxyprimaquine concentrations were measured in maternal venous plasma, capillary plasma, and breast milk samples and infant capillary plasma samples taken on days 0, 3, 7, and 13. RESULTS: In 20 mother-infant pairs, primaquine concentrations were below measurement thresholds in all but 1 infant capillary plasma sample (that contained primaquine 2.6 ng/mL), and carboxyprimaquine was likewise unmeasurable in the majority of infant samples (maximum value 25.8 ng/mL). The estimated primaquine dose received by infants, based on measured breast milk levels, was 2.98 µg/kg/day (ie, ~0.6% of a hypothetical infant daily dose of 0.5 mg/kg). There was no evidence of drug-related hemolysis in the infants. Maternal levels were comparable to levels in nonlactating patients, and adverse events in mothers were mild. CONCLUSIONS: The concentrations of primaquine in breast milk are very low and therefore very unlikely to cause adverse effects in the breastfeeding infant. Primaquine should not be withheld from mothers breastfeeding infants or young children. More information is needed in neonates. CLINICAL TRIALS REGISTRATION: NCT01780753.
引用
- Gilder ME, Hanpithakphong W, Hoglund RM, et al. Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. Clin Infect Dis. 2018. PMID: 29590311. doi:10.1093/cid/ciy235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。